Market Overview

UPDATE: Allergan Confirms Receipt of Unsolicited Proposal from Valeant, Will Review Offer

Share:
Related AGN
A Look At Dan Loeb's Diversified 13F
Paulson & Company's Q4 Moves: Healthcare And Beyond
The Best Scoring Stocks To Buy Now (Seeking Alpha)
Related VRX
Morgan Stanley Reiterates Overweight, Raises Price Target On Valeant Pharmaceuticals On New Proforma Model For SLXP
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
IBD 50 Stocks Outperform; Several Setups Emerge (Investor's Business Daily)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (“Valeant”) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the Company (the “Proposal”).

The Allergan Board of Directors, in consultation with its financial and legal advisors, will carefully review and consider the Proposal and pursue the course of action that it believes is in the best interests of the Company's stockholders. The Company's stockholders do not need to take any action at this time.

Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the Company and Latham & Watkins is serving as legal counsel to the Company.

Posted-In: News M&A Press Releases

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→